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Abstract
Background: Sexually transmitted infections (STIs) such as herpes simplex virus (HSV)-2 are associated with an increased risk
of HIV infection. Human papillomavirus (HPV) is a common STI, but little is know about its role in HIV transmission. The
objective of this study was to determine whether cervico-vaginal HPV infection increases the risk of HIV acquisition in
women independent of other common STIs.
Methods and Findings: This prospective cohort study followed 2040 HIV-negative Zimbabwean women (average age 27
years, range 18–49 years) for a median of 21 months. Participants were tested quarterly for 29 HPV types (with L1 PCR
primers) and HIV (antibody testing on blood samples with DNA or RNA PCR confirmation). HIV incidence was 2.7 per 100
woman-years. Baseline HPV prevalence was 24.5%, and the most prevalent HPV types were 58 (5.0%), 16 (4.7%), 70 (2.4%),
and 18 (2.3%). In separate regression models adjusting for baseline variables (including age, high risk partner, positive test
for STIs, positive HSV-2 serology and condom use), HIV acquisition was associated with having baseline prevalent infection
with HPV 58 (aHR 2.13; 95% CI 1.09–4.15) or HPV 70 (aHR 2.68; 95% CI 1.08–6.66). In separate regression models adjusting
for both baseline variables and time-dependent variables (including HSV-2 status, incident STIs, new sexual partner and
condom use), HIV acquisition was associated with concurrent infection with any non-oncogenic HPV type (aHR 1.70; 95% CI
1.02–2.85), any oncogenic HPV type (aHR 1.96; 95% CI 1.16–3.30), HPV 31 (aHR 4.25; 95% CI 1.81–9.97) or HPV 70 (aHR 3.30;
95% CI 1.50–7.20). Detection of any oncogenic HPV type within the previous 6 months was an independent predictor of HIV
acquisition, regardless of whether HPV status at the HIV acquisition visit was included (aHR 1.95; 95% CI 1.19–3.21) or
excluded (aHR 1.96; 95% CI 1.02–2.85) from the analysis.
Conclusions/Significance: Cervico-vaginal HPV infection was associated with an increased risk of HIV acquisition in women,
and specific HPV types were implicated in this association. The observational nature of our study precludes establishment of
causation between HPV infection and HIV acquisition. However, given the high prevalence of HPV infection in women,
further investigation of the role of HPV in HIV transmission is warranted.
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Introduction
Human papillomavirus (HPV) is a common sexually transmitted
infection (STI) and has been implicated as a causative agent of
anogenital cancers including cervical, vaginal, vulvar, and anal
cancer [1,2]. Over 30 types of HPV can infect the anogenital
epithelium, but only 18 types, designated as ‘‘oncogenic’’ types,
are implicated in the development of cancer [2]. HPV 16 and
HPV 18 are the most common oncogenic types associated with
cancer, and are targeted by recently developed vaccines [3,4,5].
The ‘‘non-oncogenic’’ HPV types are associated with hyperplastic
lesions such as genital warts.
Immune-compromised individuals such as those with HIV
suffer from higher rates of HPV infection and disease, higher rates
of relapse after treatment of HPV-related diseases, and accelerated
development of HPV-associated cancer. Little is known, however,
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10094about the converse relationship, i.e. the effect of HPV infection on
risk of HIV acquisition. Several viral and bacterial STIs, both
ulcerative and non-ulcerative, have been implicated as risk factors
for HIV acquisition including syphilis, herpes simplex virus (HSV)-
2 [6,7,8], Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas
vaginalis [9,10,11]. Having anal infection with 2 or more HPV
types was recently shown to be an independent predictor of HIV
seroconversion in a prospective cohort study of men who have sex
with men [12]. The aim of this study was to determine the
association between HPV infection and HIV acquisition in women
in the setting of an effectiveness trial of the diaphragm and
lubricant gel for HIV/STI prevention in Zimbabwe.
Methods
Study design and participants
This study was performed as a substudy within a randomized
trial studying the effect of latex diaphragm and lubricant gel
provision on HIV acquisition in the setting of counseling and
provision of male condoms in Zimbabwe (the Methods for
Improving Reproductive Health in Africa [MIRA] trial); details
about the MIRA study has been reported elsewhere (Clinical-
Trials.gov number NCT00211459) [13]. Results from this trial
demonstrated that diaphragm/gel provision added no significant
protection against acquisition of HIV [13], or cervical STIs [14],
hence data from the intervention and control arms were pooled for
this prospective cohort study. Enrollment into the substudy, as for
the parent study, was staggered over a one year period, with the
first cohort of enrolled participants followed for 24 months and the
last enrolled followed for 12 months; all participants were
scheduled for follow-up visits every 3 months. Participants in this
prospective cohort study were 2040 HIV-negative women enrolled
in MIRA at the Harare, Zimbabwe site after February 2004 who
agreed to participate in the HPV sub-study. Assessment of the
effect of cervico-vaginal HPV infection on risk of HIV acquisition
was a pre-specified aim of the HPV substudy. The provision of
diaphragm/gel in the setting of condom provision and counseling
had minimal overall effect on HPV incidence or clearance [15].
The study protocol was reviewed and approved by the University
of California San Francisco (UCSF) Committee on Human
Research, and the Medical Research Council of Zimbabwe, and
the Medicines Control Authority of Zimbabwe.
Study Procedures
At baseline (the screening or enrollment visits), a questionnaire
on demographics and sexual behavior was administered, and
participants were tested for serologic evidence of HIV and herpes
simplex virus (HSV)-2; a blood sample was obtained for syphilis
testing, and a urine specimen was obtained for PCR testing for
Neisseria gonorrhoeae, Chlamydia trachomatis and Trichomonas vaginalis
using methods described elsewhere [13]. A pelvic exam was
performed, cervical cytology was obtained, and a cervical sample
for HPV testing obtained. At quarterly visits from February 2004
to September 2006, participants were asked about recent medical
history and sexual behaviors, and samples were collected for HIV,
HSV-2, Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas
vaginalis, and HPV testing.
Women testing positive for a curable STI were treated when the
positive test result was reported. Cervical cytology was interpreted
locally in Zimbabwe (R.M.) and reported using the Bethesda
system [16]. Any woman with a result of high grade squamous
intraepithelial neoplasia, adenocarcinoma in situ or cancer at
enrollment was referred for colposcopy; women with low grade
squamous intraepithelial neoplasia or atypical squamous cells of
undetermined significance underwent repeat cytology testing in 6
months and were referred for colposcopy if that test was abnormal.
Women with colposcopically directed biopsies and/or endocervi-
cal curettage showing cervical intraepithelial neoplasia 2 or 3 or
adenocarcinoma in situ underwent diagnostic excisional proce-
dures by cone biopsy or loop excision.
Methods for HPV sample collection and testing
Cervical swabs for HPV DNA were collected by clinicians
under direct visualization of the cervix at the enrollment, 12-
month and exit visits, as previously described [15]. Self-collected
vaginal swabs were obtained at 3-month intervals after the
enrollment visit as previously described [15]. At the 12-month
visit, both clinician- and self-collected samples were collected.
HPV testing was performed using MY09/MY11 consensus HPV
L1 primers as well as primers for amplification of the human beta-
globin gene [15]. Samples that were negative for beta-globin were
considered unevaluable. Specimens that tested positive for the
consensus HPV sequence were further tested with probes specific
to 29 different HPV types (6, 11, 16, 18, 26, 31, 32, 33, 35, 39, 40,
45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 66, 68, 69, 70, 73, 83, 84,
82v), and probes for 10 HPV types in a mixture defined as ‘‘mix’’
(HPV 2, 13, 34, 42, 57, 62, 64, 67, 72, and 82). Of note, HPV 55 is
now considered to be a subtype of HPV 44 [17], but HPV 44 was
not included in the PCR probes used in this study. Specimens that
tested positive for the HPV consensus sequence, but negative for
the 39 specific types were described as having ‘‘untyped’’ HPV.
DNA samples are processed in a room kept clean of amplified
DNA. Each PCR experiment was performed with HPV-negative
and HPV-positive controls. In addition, 7 percent of all samples
are randomly subjected to a repeat PCR test to determine the
reproducibility of the results.
Methods for HIV testing
At screening and quarterly, two HIV rapid tests were performed
on finger-prick or venipuncture blood samples using Determine
HIV-1/2 (Abbott Laboratories, Tokyo, Japan) and Oraquick
(OraSure technologies, Bethlehem, PA, USA). Discordant results
of rapid tests were confirmed on serum samples by ELISA
(Vironostika, Biomirieux, Durham NC, USA). Timing of HIV
acquisition was assessed by RNA or DNA PCR testing on Dry Blot
Spot or serum samples from that visit and from prior visits until a
negative PCR test was obtained. The HIV acquisition visit was
defined as the visit at which the first positive HIV PCR test was
detected.
Statistical methods
Analyses were performed to look for associations between HIV
acquisition and HPV infection following an a priori analytic plan.
In addition to evaluating potential associations with any HPV
type, separate analyses for non-oncogenic and oncogenic HPV
types were also performed, given that oncogenic and non-
oncogenic HPV types have different biologic behaviors as reflected
by rates of persistence [18] and neoplastic potential [2]; these
analyses were not mutually exclusive and a participant could
contribute to both categories if infected with both oncogenic and
non-oncogenic HPV types. Analyses of specific HPV types (those
with prevalence $1%) were also performed. For these analyses,
‘‘mix’’ and untyped infections were excluded. Because of the
multiplicity of individual types considered, we used a conservative
Bonferroni adjustment of significance levels when interpreting the
results for single-type infections. No such adjustment was used for
infections with any type, oncogenic and non-oncogenic types. This
decision was based on the fact that in addition to pre-specifying
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and conventional correction for multiple comparisons would be
overly conservative. Because having infection with multiple HPV
types (defined as 2 or more HPV types) was not associated with a
significantly increased risk of HIV acquisition compared to
infection with a single HPV type, this variable was not included
in further analyses. In order to ascertain whether cytologic effects
of HPV accounted for any association between HPV infection and
HIV acquisition, we examined whether abnormal cytology was
predictive of HIV acquisition.
Both self-collected and clinician-collected swabs were used for
defining HPV status. If results from both collection methods were
available at the same visit, a positive result from either test
contributed to the definition of a positive HPV test. Baseline HPV
status for particular types or groups of types was defined using
HPV tests from the study enrollment visit, and used as a fixed
covariate in analyses. We defined a cumulative HPV status
indicator of ever having tested positive for a type or group of types
at baseline or during follow-up (up to and including the first HIV
positive visit for HIV converters), and considered this as a fixed
covariate in analyses. We also defined a status indicator of
persistent or non-persistent HPV infection and these were
considered as fixed covariates in analyses. A type-specific infection
was defined as persistent if any 2 consecutive tests were positive for
a specific HPV type, or if any of the following conditions were met
(if positive tests were not consecutive): for participants with 2 to 6
tests, $2 tests were positive but not .3 consecutive negative tests;
for participants with 7 to 9 tests, $3 tests were positive but not .3
consecutive negative tests; for participants with 10 tests, $4 tests
were positive but not .3 consecutive negative tests; for
participants with 11 or 12 tests, 4 tests were positive but not .4
consecutive negative tests. A type-specific HPV infection that did
not meet the above criteria was considered non-persistent.
Participants with no visits positive for type-specific HPV were
considered uninfected. Participants with HPV data from only one
study visit were excluded from this analysis.
The following measures of HPV status were also considered as
time-dependent covariates: Women were defined as having a
‘‘concurrent HPV infection’’ if HPV testing was positive at the
HIV acquisition visit. Women were defined as having a ‘‘recent
HPV infection’’ if they were positive for HPV at any visit within 6
months up to and including the HIV acquisition visit. We also
performed a ‘‘sensitivity analysis of recent HPV infection’’ of
women positive for HPV at any visit within 6 months but excluding
the HIV acquisition visit. A participant visit was excluded from the
analysis if there were no HPV results for a particular visit (for
‘‘concurrent HPV infection’’) or at any time in the preceding 6
months (for ‘‘recent HPV infection’’), resulting in different
numbers of women-visits contributing to different analyses.
Observations for visits for women who acquired HIV were
censored after the HIV acquisition visit.
Cox proportional hazards regression models were used to
evaluate associations between HPV status and HIV acquisition.
Because of the discrete nature of follow-up, the Efron correction
for tied failure times was employed in parameter estimation. The
validity of the proportional hazards assumption was evaluated via
a test of interaction between HPV status indicators and duration of
follow-up. HPV status variables (described above) were included as
either fixed (for prevalent, cumulative or persistent/non-persistent
infection) or time-dependent covariates (for concurrent or recent
infection). Although the data were pooled from the 2 arms of a
negative randomized trial, we included study arm as a variable in
the analyses in order to control for a possible effect of the
intervention. Separate models were fitted for different HPV types.
Models controlled for potentially confounding variables, including
baseline demographic characteristics and biological/clinical mea-
sures (listed in Table 1), and time dependent behavioral and
biological measures. Time dependent measures reflected results
from visit-specific interviews and clinical exams.
Results
Characteristics of the study population
Of 2089 HIV-negative female participants in MIRA who were
offered participation in the HPV sub-study, 2040 women (97.6%)
consented and 1918 (94%) of participants completed the study.
The mean age of study participants at enrollment was 27 years
(range 18–49 years), and the median follow-up period was 21
months (range 12–24 months). Detailed demographic character-
istics of participants have been published elsewhere [15] and are
summarized in Table 1. Briefly, 95.9% of women reported living
with a regular partner/husband. The mean number of lifetime
Table 1. Demographic, behavioral, and biological/clinical
characteristics of participants at baseline (N=2040).
Characteristic
Number of Women
(%) or Mean (range)
Demographic
Age
24 years or younger 758 (37.2%)
25 to 34 years 937 (45.9%)
35 years or older 345 (16.9%)
Behavioral
High risk partner: at least one indicator
1 1,343 (65.9%)
High risk behavior: at least one indicator
2 491 (24.1%)
Lifetime number of sex partners, mean (range) 1.3 (1–20)
Age at first sex, mean (range) 18.6 (10–28)
Regular sex partner circumcised
No 1,393 (68.3%)
Yes 328 (16.1%)
Don’t know 319 (15.6%)
Living together with regular sex partner 1,956 (95.9%)
Frequency of condom use in past 3 months
Never 615 (30.1%)
Sometimes 876 (43.0%)
Always 548 (26.9%)
Biological/Clinical
Normal cytology at baseline
3 1,673 (82.0%)
Tested seropositive for HSV-2 1,034 (50.8%)
Tested positive for curable STI(s)
4 140 (6.9%)
1Indicators include: Having any sexual partners test positive for HIV, suspect or
know that regular partner had other sex partners in the last 3 months, ever had
vaginal sex when partner was under influence of drugs/alcohol in last 3
months, regular partner was away from home for 1 or more months.
2Indicators include: Any exchange of sex for money/food/drugs/shelter, 2 or
more sexual partners within last 3 months, ever had vaginal sex under
influence of drugs/alcohol in last 3 months, ever used needle for injectable
drug use, ever had anal sex.
3The remainder had abnormal cytology (defined as atypical squamous cells of
undetermined significance or worse), unsatisfactory tests, or missing results.
4At least one positive test for N gonorrhoeae, C trachomatis, Trichomoniasis
vaginalis or syphilis at screening or enrollment.
doi:10.1371/journal.pone.0010094.t001
HPV Increases Risk of HIV
PLoS ONE | www.plosone.org 3 April 2010 | Volume 5 | Issue 4 | e10094sexual partners was 1.3 (range 1–20). Infection with Neisseria
gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis or syphilis was
identified in 6.9% of women at baseline, and 50.8% of women had
serologic evidence of prior exposure to HSV-2. A total of 88
women acquired HIV during follow-up, for an HIV incidence of
2.7 per 100 woman-years (95% CI=2.2, 3.4).
Characteristics of women with prevalent, incident and persistent
HPV infections in this cohort have been described elsewhere [18].
Briefly, among women with baseline evaluable HPV samples
(N=1987), prevalence of infection with any HPV type was 24.5%.
Specific HPV types with prevalence .1% were: 58 (5.0%), 16
(4.7%), 70 (2.4%), 18 (2.3%), 33 (2.0%), 53 (1.8%), 31 (1.3%), 52
(1.3%) and 61 (1.0%). Incidence of any new HPV type within 11–
16 months after enrollment was 23.3%. HPV types with incidence
.1% were: 58 (2.4%), 16 (2.1%), 70 (1.7%), 18 (1.3%), 53 (1.2%),
31 (1.2%), 33(1.1%), 61 (1.1%) and 52 (1.0%).
Effect of prevalent HPV infection on risk of HIV
acquisition
We first examined whether prevalent HPV infection (defined as
HPV detection at baseline) was predictive of HIV acquisition. In
regression models adjusted for baseline variables associated with
HIV acquisition, being positive at baseline for any HPV type or for
any oncogenic HPV type was marginally associated, and being
positive for HPV type 58 or 70 was significantly associated with
HIV acquisition during the study (Table 2).
Effect of HPV infection during study participation on risk
of HIV acquisition
HPV status at baseline does not necessarily reflect HPV status at
later time points, since prevalent HPV infections can clear
spontaneously or persist, and incident infections with other HPV
types can occur over time. We therefore examined whether having
an HPV infection at any time during study participation (baseline
or follow-up) was associated with an increased risk of HIV
acquisition. For this analysis, each participant was defined as HPV
uninfected (negative for type-specific HPV at every visit) or HPV
infected (positive for type-specific HPV at any visit up to and
including the HIV acquisition visit). In regression models adjusted
for baseline variables associated with HIV acquisition (as defined
in Table 2 footnote), the following HPV status indicators were
independently associated with HIV acquisition: being positive at
any time during study participation for any non-oncogenic HPV
type (adjusted HR [aHR]=1.66; 95% CI=1.06–2.62), for HPV
31 (aHR=2.23; 95% CI=1.11–4.46) or for HPV 58 (aHR=2.01;
95% CI=1.18–3.41). ). No significant deviations from propor-
tional hazards were observed.
Effect of abnormal cytology and persistent or non-
persistent HPV infection on risk of HIV acquisition
Since HPV infection can result in epithelial lesions that might
increase susceptibility to HIV, we examined the association
between cytology results (collected at enrollment) and HIV
acquisition during the study; having an abnormal cytology result
(atypical squamous cells of undetermined significance or a more
severe result) was not significantly associated with an increased risk
of HIV acquisition (HR=1.38; 95% CI=0.80, 2.34). Persistent
type-specific HPV infection is a well-established risk factor for
development of cervical intraepithelial neoplasia. Therefore, we
explored the association between persistent HPV infections and
HIV risk in study participants. We defined an HPV infection as
being persistent or non-persistent based on the proportion of
positive type-specific tests for each participant. In regression
models adjusted for baseline variables, persistent infections had no
effect on HIV risk, but non-persistent infection with either
oncogenic or non-oncogenic HPV types were both significantly
associated with an increased risk of HIV acquisition (Table 3). In
analyses of type-specific HPV infections adjusted for baseline
variables, persistent infections did not confer risk regardless of the
HPV type whereas non-persistent infections with the following
HPV types were significantly associated with an increased risk:
HPV 31 (aHR=3.03, 95% CI=1.39, 6.58); HPV 53
(aHR=2.35, 95% CI=1.28, 4.94); and HPV 58 (aHR=2.52,
95% CI=1.28, 4.94).
Table 2. Prevalent HPV infection as a predictor of HIV acquisition.
HPV status
Unadjusted
Hazard Ratio
95% Confidence
Interval p-value
Adjusted
Hazard Ratio
1
95% Confidence
Interval p-value
Any HPV 1.84 1.19–2.86 0.006 1.55 0.99–2.42 0.053
Any non-oncogenic HPV
2 1.52 0.74–3.15 0.27 1.22 0.58–2.55 0.595
Any oncogenic HPV
3 1.78 1.10–2.86 0.018 1.56 0.96–2.52 0.069
HPV16 1.34 0.54–3.30 0.524 1.27 0.51–3.14 0.604
HPV18 0.49 0.68–3.53 0.480 0.47 0.06–3.37 0.451
HPV31 1.87 0.46–7.60 0.381 1.92 0.47–7.87 0.366
HPV33 1.82 0.58–5.77 0.306 1.51 0.47–4.80 0.486
HPV52 0.97 0.13–6.94 0.973 0.86 0.12–6.23 0.882
HPV53 1.31 0.32–5.30 0.709 1.11 0.27–4.51 0.888
HPV58 2.58 1.34–5.00 0.005 2.13 1.09–4.15 0.026
HPV61 1.23 0.17–8.83 0.838 1.09 0.15–7.84 0.935
HPV70 3.08 1.25–7.60 0.015 2.68 1.08–6.66 0.033
1Adjusted for the following baseline characteristics: high risk partner (as defined in Table 1 footnote), positive test for N gonorrhoeae, C trachomatis, Trichomoniasis
vaginalis or syphilis, cohabiting with regular sexual partner, age 25–34 years or .35 years (compared to age #24 years), positive serology for HSV-2, no condom use
within the prior 3 months (compared to sometimes or always using condoms), and regular partner not circumcised.
2Non-oncogenic HPV types defined as types 6, 11, 32, 40, 54, 55, 61, 69, 70, 83, 84, ‘‘mix’’, and untyped.
3Oncogenic HPV types defined as 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82v.
doi:10.1371/journal.pone.0010094.t002
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acquisition
To assess the effect of HPV infection at the time of HIV
acquisition, we analyzed the effect of concurrent HPV infection on
the risk of HIV acquisition. In unadjusted analyses, HIV acquisition
was significantly associated with having concurrent infection with
any non-oncogenic HPV type, with any oncogenic HPV type, or
with HPV type 31, 58 or 70 (Table 4). Given that risk factors for
acquisition of HIV can also change over time, we controlled for
time-dependent variables such as HSV-2 serology status, incident
STIs, report of a new sexual partner and report of condom use at
the last sexual encounter prior to the current visit, as well as
baseline characteristics. HIV acquisition was independently associ-
ated with having concurrent infection with any non-oncogenic
HPV type, with any oncogenic HPV type, or with HPV type 31 or
70 (Table 4). Significance of results for the single-type infections (31
and 70) was preserved at the 5% level after Bonferroni adjustment
of p-values to account for 9 separate comparisons.
Effect of recent HPV infection on risk of HIV acquisition
In order to determine whether HPV status preceding the time of
HIV acquisition increased the risk of HIV infection, we defined
‘‘recent HPV infection’’ as HPV status at any visit within the
previous 6 months, including the current visit. Having a recent
HPV infection with any HPV type or with any oncogenic HPV
type was independently associated with an increased risk of HIV
acquisition (Table 5). We conducted a sensitivity analysis to
determine the effect of recent HPV infection within the past 6
months but excluding the current visit; having an HPV infection
with any non-oncogenic or oncogenic HPV types was indepen-
dently associated with an increased risk of HIV acquisition
(Table 5).
Table 3. Persistent and non-persistent HPV infection as predictors of HIV acquisition.
HPV Status Unadjusted HR
95% confidence
interval P value Adjusted HR
1
95% confidence
interval P value
Any non-oncogenic HPV
2:
Persistent 1.50 0.56–1.84 0.279 1.24 0.59–2.60 0.574
Non-persistent 2.42 1.26–3.25 ,0.001 2.09 1.27–3.44 0.004
Any oncogenic HPV
3:
Persistent 1.01 0.72, 3.15 0.969 0.82 0.45–1.50 0.523
Non-persistent 2.02 1.47, 3.98 0.003 1.67 1.03–2.70 0.038
1Adjusted for the following baseline characteristics: high risk partner (as defined in Table 1 footnote), positive test for N gonorrhoeae, C trachomatis, Trichomoniasis
vaginalis or syphilis, cohabiting with sexual partner, age 25–34 years or .35 years (compared to age #24 years), and positive serology for HSV-2.
2Non-oncogenic HPV types defined as types 6, 11, 32, 40, 54, 55, 61, 69, 70, 83, 84 (mixed and untyped infections are excluded from the analysis).
3Oncogenic HPV types defined as 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82v.
doi:10.1371/journal.pone.0010094.t003
Table 4. Concurrent HPV infection as a predictor of HIV acquisition.
HPV Status
Unadjusted
Hazard Ratio
95% confidence
interval p-value
Adjusted
Hazard Ratio
1
95% confidence
interval p-value
Any HPV type 2.25 1.45–3.75 ,0.001 1.59 0.98–2.58 0.063
Any non-oncogenic HPV
2 2.37 1.45–3.83 ,0.001 1.70 1.02–2.85 0.042
Any oncogenic HPV
3 2.65 1.65–4.26 ,0.001 1.96 1.16–3.30 0.012
HPV 16 1.80 0.83–3.92 0.139 1.38 0.61–3.13 0.445
HPV 18 1.95 0.71–5.36 0.194 1.37 0.47–4.02 0.568
HPV 31 6.23 3.00–13.00 ,0.001 4.25 1.81–9.97 0.001
HPV 33 2.13 0.78–5.83 0.142 1.34 0.49–3.88 0.537
HPV 52 0.84 0.12–6.02 0.859 0.73 1.00–5.45 0.759
HPV 53 2.43 0.89–6.65 0.085 2.21 0.78–6.24 0.133
HPV 58 2.82 1.40–5.66 0.004 1.82 0.83–4.00 0.135
HPV 61 0.56 0.77–4.01 0.561 0.46 0.06–3.37 0.448
HPV 70 3.53 1.62–7.69 0.001 3.30 1.50–7.29 0.003
1Adjusted for Baseline variables: study arm, high risk behavior (as defined in Table 1 footnote), high risk partner (as defined in Table 1 footnote), positive test for N
gonorrhoeae, C trachomatis, Trichomoniasis vaginalis or syphilis, cohabiting with sexual partner, age 25–34 years or .35 years (compared to age #24 years), positive
serology for HSV-2, no condom use within the prior 3 months (compared to sometimes or always using condoms), and regular partner not circumcised and Time-
dependent variables: condom non-use since last visit; new partner since last visit; circumcision status of new partner; incident infection since the last visit with HSV-2, N
gonorrhoeae, C trachomatis, Trichomoniasis vaginalis.
2Non-oncogenic types defined as types 6, 11, 32, 40, 54, 55, 61, 69, 70, 83, 84, ‘‘mix’’, and untyped.
3Oncogenic types defined as 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82v.
doi:10.1371/journal.pone.0010094.t004
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In this large cohort of Zimbabwean women, we found
consistently increased risk of HIV acquisition associated with
cervico-vaginal HPV infection, and specific HPV types (HPV 31,
58 and 70) were implicated in the association. These results
suggest a previously unrecognized role of HPV in HIV acquisition
among women. An obvious explanation for the observed
association is that it is attributable to a partner with both
infections, and we cannot definitively rule out the effect of sexual
exposure to both infections as the explanation for the association.
However, demographic information collected at enrollment and at
each quarterly visit allowed us to control for time-dependent
variables such as new sexual partners, HSV-2 serostatus, new
STIs, or high-risk behavior by the participant or her regular
partner. In addition, the results from our sensitivity analysis
suggest that HPV infection preceded HIV acquisition.
Most HPV infections are cleared by innate and adaptive
immune mechanisms [19], making it is biologically plausible that
the local immune response elicited by HPV infection predisposes
to HIV acquisition, and that women in the process of clearing an
HPV infection might be at increased risk. This possibility is
supported by our finding that non-persistent HPV infections were
associated with increased risk of HIV acquisition whereas
persistent infections were not. HPV infection does not cause
epithelial ulcerative lesions but rather is associated with hyper-
proliferative changes such as warts, cervical intraepithelial
neoplasia or cancer; these lesions are known to be infiltrated by
HIV target cells such as lymphocytes and macrophages [20,21,22].
Persistent HPV infections are associated with an increased risk of
developing precancerous lesions, but in our study were not
associated with an increased risk of HIV acquisition. These results
suggest that clearance of HPV infection rather than the dysplastic
effect of HPV on epithelial cells confers HIV risk. We do not
known whether the women in this study had HPV-associated
lesions at the time of HIV acquisition, and although we found no
significant association between abnormal cytology (which detects
HPV-associated lesions) and risk of HIV infection, this result may
have been limited by lack of power. Additional studies incorpo-
rating frequent cytological and colposcopic evaluations are
required to definitively establish the role of HPV-related lesions
in HIV transmission. The observed association between HPV
infection and HIV acquisition might also be due to unmeasured
confounding variables such as social networks; although we
adjusted for multiple variables that measure risk of HIV through
sexual activity, this report cannot definitively establish the exact
role of HPV infection in risk of HIV acquisition.
Our finding of HPV type-specific associations (HPV 31, 58 and
70) raises the possibility that biological processes might underlie
the association with HIV risk. HPV 70 is a non-oncogenic HPV
type in clade A7 whereas HPV 31 and 58 are oncogenic HPV
types in clade A9. HPV16, another member of clade A9, is the
most common HPV type in the African continent [23]; it was
second in prevalence after HPV 58 in the Zimbabwean women in
our study (4.7%), but it did not confer significantly increased risk of
HIV acquisition in any of our analyses. The reason for the HIV
risk association with a subset of HPV types is unknown but may
reflect type-specific differences in the host immune response to
HPV. The relatively high prevalence of HPV 58 and HPV 70 in
this cohort, and the observed association of these types with HIV
acquisition, suggest that the contribution of HPV to HIV
acquisition risk may vary in different populations depending on
the distribution of HPV types and host genetic polymorphisms.
The currently available HPV vaccines target HPV 6, 11, 16 and
18, which are not the HPV types identified with HIV risk in our
study (HPV 31, 58 and 70). Further investigation into host and
HPV type-specific differences in the immune/inflammatory
responses to HPV infection will help to elucidate possible
biological mechanisms by which HPV infection could contribute
to HIV transmission.
The strengths of our study are the large sample size, the high
retention rate, and the abundance of data about HPV status and
risk factors collected at frequent intervals over time. A limitation
of this study is that the commonly used definition of HPV
infection cannot differentiate between the presence of biologi-
cally active HPV versus the detection of HPV DNA due to
deposition in the genital tract during a recent sexual encounter.
For this reason and due to the observational study design, these
results cannot establish causation between HPV infection and
HIV acquisition, but they suggest that HPV is a potentially
significant risk factor for HIV acquisition in women. To date,
little is known about the association between HPV and HIV
transmission. In a recent study in men who have sex with men,
anal infection with 2 or more HPV types significantly increased
the risk of HIV infection (HR 3.5, 95% CI=1.2–10.6) [12].
Given the high prevalence of anogenital HPV infection, further
investigation of the role of HPV in HIV acquisition is
warranted. A better understanding of the factors underlying
the HPV-HIV association will improve our understanding of the
pathogenesis of HIV transmission.
Table 5. Recent HPV infection (within 6 months of HIV acquisition visit) as a predictor of HIV acquisition.
Infection with:
Including current visit
Adjusted Hazards Ratio
1
95% confidence
interval p- value
Excluding current
visit Adjusted Hazards Ratio
1
95% confidence
interval p-value
Any HPV 1.63 1.00–2.66 0.052 1.59 0.97–2.58 0.063
Any Non-oncogenic HPV
2 1.50 0.92–2.43 0.104 1.70 1.02–2.85 0.042
Any Oncogenic HPV
3 1.95 1.19–3.21 0.008 1.96 1.16–3.30 0.012
1Adjusted for Baseline variables: study arm, high risk behavior (as defined in Table 1 footnote), high risk partner (as defined in Table 1 footnote), positive test for N
gonorrhoeae, C trachomatis, Trichomoniasis vaginalis or syphilis, cohabiting with sexual partner, age 25–34 years or .35 years (compared to age #24 years), positive
serology for HSV-2, no condom use within the prior 3 months (compared to sometimes or always using condoms), and regular partner not circumcised and Time-
dependent variables: condom non-use since last visit; new partner since last visit; circumcision status of new partner; incident infection since the last visit with HSV-2, N
gonorrhoeae, C trachomatis, Trichomoniasis vaginalis.
2Non-oncogenic types defined as types 6, 11, 32, 40, 54, 55, 61, 69, 70, 83, 84, ‘‘mix’’, and untyped.
3Oncogenic types defined as 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82v.
doi:10.1371/journal.pone.0010094.t005
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